All In Biotech

Drug Trial Radar · NCT05005234

A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations

An Open-label, Multi-center Phase I/II Clinical Study Evaluating the Safety/Tolerability, Pharmacokinetics, and Effectiveness of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations

Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

334

Actual

Start

Sep 13, 2021

Primary completion

Feb 20, 2023

Study completion Dec 20, 2024

Sponsor

Sponsor type
Industry
First posted
Aug 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase Ia: To evaluate the safety/tolerability of GFH925 in subjects with KRAS G12C-mutated advanced solid tumors; To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of GFH925. Phase Ib: To evaluate the efficacy of GFH925 in subjects with KRAS G12C mutant advanced colorectal cancer or other tumors. Phase II: To evaluate the efficacy of GFH925 in subjects with KRAS G12C mutant advanced non-small cell lung cancer (NSCLC).

Conditions

  • KRAS G12C

Interventions

  • GFH925Drug

    Administered as an oral tablet formulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs); changes in laboratory tests, vital signs, physical examinations, electrocardiograms (ECGs)Time frame: Baseline to 24 Months
  2. Phase Ia: Incidence of dose-limiting toxicity (DLT) eventsTime frame: At the end of Cycle 1(each cycle is 21 days)
  3. Phase Ib: ORR per RECIST 1.1Time frame: Continuous evaluation during treatment
  4. Phase II: ORR assessed by Independent Radiographic Review Committee (IRRC) according to RECIST 1.1Time frame: Continuous evaluation during treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.